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Abstract
Introduction: The purpose of this study was to evaluate the safety, tolerability, pharmacokinetics (PK) and
pharmacodynamics (PD) of the humanized anti-CD4 monoclonal antibody MTRX1011A in a randomized, double-
blind placebo-controlled Phase 1 study in patients with rheumatoid arthritis (RA).
Methods: In the single ascending dose (SAD) portion of the study, patients received single doses of a placebo or
MTRX1011A at 0.3, 1.0, 3.5 and 7.0 mg/kg intravenously (IV) or 1.0 and 3.5 mg/kg subcutaneously (SC), followed by
five weeks of evaluation. In the multi-dose (MD) portion of the study, placebo or MTRX1011A was administered
weekly for eight doses at 1.5 or 3.5 mg/kg SC, or 5 mg/kg IV, followed by eight weeks of evaluation.
Results: MTRX1011A was well tolerated in the SAD phase up to 7 mg/kg IV and in the MD phase up to 1.5 mg/kg
SC. At weekly doses of 3.5 mg/kg SC and 5 mg/kg IV, a moderate pruritic papular rash was observed in some
MTRX1011A-treated patients, which was considered a dose-limiting toxicity for this clinical indication. No serious
adverse events occurred in any cohort. Reduction in disease activity was modest. PD assessments demonstrated
that MTRX1011A induced a dose-dependent down-modulation of CD4 expression on peripheral blood CD4 T cells,
CD4 receptor occupancy, increases in serum sCD4-MTRX1011A complexes and up-regulation of CD69 on T cells,
but was non-depleting.
Conclusions: The maximum tolerated dose of MTRX1011A was 1.5 mg/kg SC administered weekly. At this dose
MTRX1011A did not achieve maximum PD activity expected to be required for reduction in disease activity.
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Introduction
Although the etiology and pathogenesis of rheumatoid
arthritis (RA) remain to be fully elucidated, the disease
is characterized in part by a cell-mediated immune
response. Many novel therapeutics have attempted to
target cell-mediated pathways, including those targeting
CD4 T cells. The first line of treatment typically
involves the use of disease-modifying anti-rheumatic
drugs (DMARDs). Biologics may be subsequently added
to the treatment repertoire in inadequate responders.
Despite these treatments available for RA, a significant
number of patients are unresponsive or intolerant to
current therapies, and a significant need remains for
novel effective treatments for RA [1,2].
A critical role of CD4 T cells in the pathogenesis of
RA has been described by multiple groups. Increased
numbers of CD4 T cells are detected in inflamed RA
synovium, elevated levels of activated T cells in the
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ease susceptibility is associated with certain major histo-
compatibility complex class II (MHCII) alleles [3-6].
Preclinical studies with anti-CD4 therapeutics have pro-
vided further evidence for the critical role of CD4 T
cells in the pathogenesis of disease [7]. Abatacept is an
approved therapeutic for patients with RA that reduces
disease activity by blocking the CD80/CD86:CD28 co-
stimulation signal of CD4 T cells [8]. MTRX1011A is a
humanized IgG1 anti-CD4 monoclonal antibody (MAb)
derived from a previously described TRX1 antibody [9].
It binds with high affinity to human CD4 T cells with
an equilibrium dissociation constant (KD)l e s st h a n1
nM. MTRX1011A down-modulates cell surface expres-
sion of CD4 and inhibits the function of residual surface
CD4 by blocking its interaction with MHC II. An amino
acid substitution of N297A was introduced to impair
binding to Fcg receptors and consequently prevent Fc-
mediated effector function [10,11], rendering the anti-
body non-depleting in vivo [12,13]. In MTRX1011A, an
additional single amino acid substitution was made in
the Fc region of the antibody (N434H) to improve its
binding to the neonatal Fc receptor (FcRn) [14]. This
improved binding to FcRn was expected to enhance
antibody recycling from the endosome back to the cir-
culation and protect it from degradation in the lyso-
some, therefore decreasing MTRX1011A in vivo
clearance [14].
Several prior therapeutics targeting the CD4 molecule
have been reported. Studies examining the anti-CD4
antibodies keliximab, clenoliximab, and 412W94,
resulted in varying levels of clinical response, suggesting
that CD4 may represent a valid target for the treatment
of RA [15-17]. Differences in RA patient populations
studied and dosing regimens employed might account
for the different clinical outcomes observed; in addition
keliximab, 412W94, and cM-T412, a fourth anti-CD4
antibody evaluated in RA patients, depleted peripheral
CD4 T cells [18,19]. A dose-limiting rash was observed
in several studies with both depleting and non-depleting
anti-CD4 antibodies [15,16,20]; however, detailed
descriptions and evaluations of these rashes were lim-
ited. The efficacy of non-depleting anti-CD4 antibodies
is thought to be mediated by down-modulation of the
CD4 receptor on T cells through internalization of the
antibody-receptor complex and subsequent blocking of
the interaction of the remaining CD4 co-receptor with
MHCII on antigen presenting cells, resulting in reduced
T cell activation. Pharmacodynamic (PD) evaluations
with cM-T412 in patients with RA suggested that sus-
tained maximum CD4 occupancy on peripheral blood T
cells was required to induce CD4 occupancy on T cells
in the synovium [21]. Studies by Mason et al.s u g g e s t e d
that sustained CD4 down-modulation and CD4 receptor
occupancy are required for non-depleting anti-CD4 anti-
bodies to be effective [15]. Furthermore, studies in col-
lagen-induced arthritis mouse models demonstrated that
CD4 T cell depletion is not required for efficacy [7], and
this was subsequently confirmed in clinical studies with
clenoliximab. Taken together, these studies suggest that
clinical efficacy from anti-CD4 antibodies could be
achieved by maintaining maximum CD4 occupancy and
down-modulation throughout the dosing period.
We report the results of a phase I study in which the
safety, tolerability, pharmacokinetics (PK) and PD of
MTRX1011A were evaluated in RA patients. The aim of
this study was to identify a dose of MTRX1011A that
was safe, well tolerated and maintained maximum CD4
occupancy and down-modulation that was not asso-
ciated with rash. Extensive exploratory biomarkers were
incorporated to investigate the mechanism of action of
MTRX1011A.
Materials and methods
Patients
Sixty-six RA patients were enrolled at 16 study sites in
the US. All sites were Institutional Review Board-
approved, and all patients provided voluntary written
informed consent (Registered at ClinicalTrials.gov;
NCT00718588). Eligible patients were between the ages
of 18 and 80 years and fulfilled the American College of
Rheumatology (ACR) 1987 revised criteria for RA.
Enrollment criteria required patients to have CD4 T cell
counts above the lower limit of normal, to be on a
stable regimen of anti-rheumatic therapy (four to eight
weeks for DMARDS; two weeks for nonsteroidal anti-
inflammatory drugs (NSAIDs), four weeks for steroids),
and to have an appropriate washout period after discon-
tinuation of any previous biologic treatments. Addition-
ally, patients enrolled in the multiple dose (MD) phase
of the study were required to have at least three swollen
and tender joints and had shown an inadequate
response or intolerance to at least one biological agent.
Significant exclusion criteria were recurrent or chronic
infection, and any significant medical condition that
would predispose to an increased risk by participation
in a clinical trial, and the presence of other autoimmune
disease with the exception of secondary Sjögren’s
syndrome.
Study design
I nt h es i n g l ea s c e n d i n gd o s e( S A D )p h a s e ,3 0p a t i e n t s
were treated in six cohorts of 5 patients each (1 rando-
mized to placebo and 4 randomized to MTRX1011A),
with four IV doses (0.3, 1.0, 3.5 and 7.0 mg/kg) and two
SC dose levels (1.0 and 3.5 mg/kg) of MTRX1011A.
Dose escalation occurred after safety was established for
at least 14 days from the previous cohort. Initiation of
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table safety data from the SAD phase up to 14 days of
all patients in the high dose SC and IV cohorts. Thirty-
six patients were randomized into the MD phase of the
study and received MTRX1011A or placebo weekly for
eight doses. Two SC cohorts consisted of 12 patients
receiving MTRX1011A (at 1.5 mg/kg and 3.5 mg/kg)
and 3 receiving placebo weekly. One IV cohort consisted
of five patients receiving MTRX1011A (at 5.0 mg/kg)
and one receiving placebo weekly. Patients were fol-
lowed for five or eight weeks following dose administra-
tion in the SAD and MD phase respectively.
Clinical evaluations
T h ep r i m a r yo u t c o m em e a s u r e so ft h es t u d yw e r et h e
safety and tolerability. Exploratory outcome measures in
the multi-dose phase of the study included the propor-
tion of patients who achieved ACR20/50/70, and several
patient-reported outcome measures. Dermatologic con-
sultation, photography and skin biopsy were encouraged
if patients experienced rash.
Pharmacokinetics
Serum samples were collected to measure the concen-
tration of total MTRX1011A and to detect the presence
of potential anti-therapeutic antibodies by ELISA as pre-
viously described [14].
Pharmacodynamics
Whole blood samples were collected for flow cytometric
analysis of lymphocyte subsets. First, a standard T, B,
NK flow cytometry panel (BD Biosciences (San Jose,
CA, USA) was used for cell quantification. Due to inter-
ference of MTRX1011A with the anti-CD4 antibody in
the flow cytometry panel, CD4 T cells were identified as
CD3+CD8- T cells and in an additional exploratory
panel using an anti-CD4 antibody (clone MT-441) in
which binding was not affected by MTRX1011A. Sec-
ond, to evaluate internalization of CD4 by MTRX1011A,
expression levels of CD4 were determined using the
non-competing anti-CD4 antibody (clone MT-441).
Receptor occupancy of CD4 was determined by staining
with fluorescently labeled MTRX1011A. CD4 expression
and occupancy data were expressed as change from pre-
dose values (% baseline) for placebo and MTRX1011A
groups. Lastly, T cell subsets were classified into mem-
ory and naïve subsets using CD45RA antibody, and the
expression of the activation markers CD25 and CD69
was characterized. B cells subsets were enumerated by
naïve and memory subpopulations using CD27, CD38,
and IgD surface markers.
Serum levels of total soluble CD4 and soluble CD25
were determined by ELISA. Serum levels of pro-inflam-
matory cytokines TNF-a,I L - 6 ,G M - C S F ,I F N g,I L - 1 0 ,
IL12p70, IL-1b, IL2, and IL-8 were measured using mul-
tiplex electrochemiluminescence assays on the Meso
Scale Discovery SECTOR Imager 6000 platform
(Gaithersburg, MD, USA).
Statistical analysis
All data analyses were conducted using descriptive sta-
tistics, which were based on the intent-to-treat principle.
Results were summarized separately for the placebo
group (pooled across all dosage levels) and for each of
the nine MTRX1011A cohorts. The sample size for the
SAD phase was chosen to detect major intolerability sig-
nals. The sample size in the MD phase (the 1.5 and 3.5
mg/kg SC cohorts) was chosen to better understand the
PK and PD properties of MTRX1011A and to explore
possible clinical benefit of MTRX1011A.
Results
Patient baseline demographics, characteristics, and
disposition
Patient disposition is reflected in Figure 1. A total of 66
patients were randomized, and their baseline character-
istics are presented in Table 1. There were no signifi-
cant differences in baseline characteristics between any
of the treatment groups. The majority of patients were
Caucasian females, mean age for all randomized patients
was 54 years, and was balanced between groups. The
mean disease duration ranged from 3.8 to 8.1 years.
Patients in the MD phase had higher C-reactive protein)
CRP levels, erythrocyte sedimentation rate (ESR) and
tender joint count (TJC) than patients in the SAD
phase, reflective of the differences in enrollment criteria
for the SAD and MD phases. Baseline Disease Activity
28 joints-C-reactive protein scores (DAS28(4)-CRP)
scores ranged from 4.8 to 5.9. Patients in the MD phase
had slightly lower incidence of RF positivity than
patients in the SAD phase, despite long standing disease
and 100% anti-cyclic citrullinated peptide (CCP)
positivity.
Five patients withdrew early from the study, four of
those were based on decisions by the patient, and one
patient was dosed SC instead of IV in the last cohort
and was withdrawn from the study due to increased dis-
ease activity judged by the site investigator several days
later. This patient was replaced according to protocol
specified guidance. However, dosing was later discontin-
ued in the 5 mg/kg IV weekly cohort per protocol rules
secondary to dose-limiting toxicities of rash.
Safety
Adverse events (AEs) reported in ≥ 2 patients are shown
in Table 2. The overall incidence of AEs was higher in
patients treated with MTRX1011A than in those treated
with placebo.
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MTRX1011A experienced at least one drug-related AE
compared with one (16.7%) patient who received pla-
c e b o .O n ep a t i e n ti nt h eS A Dp h a s ew h or e c e i v e d
MTRX1011A experienced pruritis one day after dosing
that resolved spontaneously.
MD Phase: Five patients (17.2%) receiving
MTRX1011A experienced at least one drug-related AE
Single Ascending Dose 
Multiple Ascending Dose 
Screened 
N=61  
Randomized 
N=36 
MTRX1011A  
1.5 mg/kg SC 
n=12 
Placebo SC 
n=3  
MTRX1011A 
3.5 mg/kg SC 
n=12  
Placebo SC 
n=3 
MTRX1011A  
5 mg/kg IV 
n=5 
Placebo IV 
n=1 
93% completed  
through Week 16  
 
1 (7%) discontinued  
after receiving 8 
doses  
3 (50%) completed 
through Week 16 
 
2 (33%) discontinued  
after receiving 4 doses  
due to DLT rash 
 
1 (17%) discontinued  
after receiving 1 dose  
 
13 (87%) completed  
through Week 16 
 
1 (7%) discontinued  
after receiving 8 doses 
 
1 (7%) discontinued  
after receiving 5 doses  
due to RA disease flare 
Screened 
N=49 
Randomized 
N=30 
MTRX1011A  
0.3 mg/kg IV 
n=4  
Placebo IV 
n=1 
MTRX1011A  
1 mg/kg IV 
n=4  
Placebo IV 
n=1 
MTRX1011A  
1 mg/kg SC 
n=4  
Placebo SC 
n=1 
MTRX1011A 
3.5 mg/kg IV 
n=4  
Placebo IV 
n=1 
MTRX1011A  
3.5 mg/kg SC 
n=4  
Placebo SC 
n=1 
MTRX1011A  
7 mg/kg IV 
n=4 
Placebo IV 
n=1 
97% completed through Week 5 
Figure 1 Patient disposition. Single ascending dose and multiple dose stages.
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testinal disorders were reported only in MTRX1011A-
treated patients (27.6%) and were mild. One
MTRX1011A-treated patient in the MD phase 3.5 mg/
kg SC cohort experienced oral candidiasis (considered a
dose limiting toxicity) and a moderate papular pruritic
rash both during and after dosing.
Because an increased incidence of rash was observed
in previous anti-CD4 clinical studies, special considera-
tion was given to cutaneous events in the study. In the
MD phase, 10 (34.5%) MTRX1011A-treated patients
versus no placebo patients reported cutaneous disorders
overall. There were no cases of drug-related rash in the
1.5 mg/kg SC cohort; however, one patient in this
Table 1 Demographics and baseline characteristics of the patients
Single dose phase Multi dose phase
Characteristics Placebo MTRX1011A Placebo MTRX1011A
Gender
(Female:Male)
4:2 15:9 6:1 24:5
Age, years
Mean (range)
51 (41 to 64) 56 (27 to 77) 57 (43 to 57) 53 (25 to 76)
Race
(White:Black)
5:1 23:1 7:0 24:5
Disease Duration (median years) 3.8 5.7 5.0 8.1
RF positive, % 66.7 58.3 42.9 34.5
CCP positive, % 100 100 100 100
RF and anti-CCP positive, % 66.7 58.3 42.9 34.5
Concomitant
Meds:
% on MTX 67 75 57 66
%o n 0 4 1 4 0
leflunomide
% on steroids
33 50 43 48
CRP, mg/dL
Mean (range)
0.53 (0.50 to 0.93) 0.65 (0.04 to 2.89) 1.68 (003 to 3.99) 1.11 (0.02 to 8.21)
ESR, mm/hour
Mean (range)
26 (0 to 42) 25 (4 to 49) 47 (15 to 120) 40 (0 to 110)
SJC
Mean (range)
17 (10 to 33) 17 (0 to 63) 7 (0 to 16) 18 (2 to 59)
TJC
Mean (range)
25 (6 to 44) 31 (1 to 68) 36 (10 to 53) 43 (58 to 68)
Baseline DAS-CRP 4.8 (3.85 to 5.68) 5.15 (2.66 to 7.17) 5.43 (4.28 to 6.62) 5.93 (3.74 to 8)
anti-CCP, anti-cyclic citrullinated peptide antibodies; CRP, C-reactive protein; DAS, disease activity score; ESR, erythrocyte sedimentation rate; MTX, methotrexate;
RF, rheumatoid factor; SJC, swollen joint count; TJC, tender joint count; TNF, tumor necrosis factor.
RF positive was defined as RF ≥20 IU/ml; anti-CCP positive was defined as anti-CCP ≥5 U/ml.
Table 2 Adverse events in ≥2 patients
SAD Stage MD Stage
No. (%) Patients Placebo
(n =6 )
All Active
(n = 24)
Placebo
(n =7 )
1.5 mg/kg
(SC) (n = 12)
3.5 mg/kg
(SC) (n = 12)
5.0 mg/kg
(IV)(n =5 )
All Active
(n = 29)
Adverse Events
Any event 1 (17) 6 (25) 0 (0) 1 (8) 3 (25) 1 (20) 5 (17)
Nausea 0 (0) 2 (8) 0 (0) 0 (0) 1 (8) 0 (0) 1 (3)
Flank pain 0 (0) 2 (8) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Fatigue 0 (0) 0 (0) 0 (0) 1 (8) 1 (8) 0 (0) 2 (7)
Pruritis 0 (0) 0 (0) 0 (0) 0 (0) 1 (8) 1 (20) 2 (7)
Rash 0 (0) 0 (0) 0 (0) 0 (0) 1 (8) 1 (20) 2 (7)
Serious Adverse Events
Any event 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
IV, intravenous; MD, multiple dose; SAD, single ascending dose; SC, subcutaneous.
*Adverse events determined by investigators to be related to MTRX1011A by preferred term in ≥ 2 patients.
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in the higher dose cohorts, the rash was observed after
patients received three or four doses (3 out of 12 active
treatment subjects in the 3.5 mg/kg SC cohort and 2
out of 4 active treatment subjects in the 5.0 mg/kg IV
cohort). In all cases, the rash resolved when
MTRX1011A was discontinued or the rash was treated
with topical or oral agents (for example, antihistamines
and/or corticosteroids). The rash was usually preceded
by the onset of pruritis at least several hours to days
before the visible rash. In two patients, the rash recurred
with re-exposure to the drug, in one after receiving the
last dose and in the other after each consecutive dose of
MTRX1011A. The rash was widely distributed through-
out the body – on the abdomen, back, and extremities.
In most cases the rash was erythematosus, raised, papu-
lar and intensely pruritic (resulting in excoriations in
several patients). In two of the patients, a dermatologic
consultation and skin biopsy was obtained. One biopsy
from a patient in the MD 3.5 mg/kg SC cohort revealed
a superficial perivascular infiltrate of lymphocytes, his-
tiocytes and a few eosinophils in the dermis. The epider-
mis demonstrated spongiosis with overlying compact
hyperkeratosis and focal parakeratosis. The other biopsy
was collected from a patient in the MD 5 mg/kg IV
cohort, and revealed palisaded neutrophilic and granulo-
matous dermatitis with necrobiosis of collagen fibers in
the upper dermis.
Laboratory parameters
No pattern of clinically significant changes was observed
for the hematology, chemistry, and urinalysis parameters
in any cohort. Additionally, no sustained pattern of CD4
+ T-cell depletion was observed in any cohort. The
mean peripheral blood CD4 T cell counts are presented
in Figure 2. In some patients a transitory CD4 T cell
reduction was observed immediately following adminis-
tration of MTRX1011A. CD4 T cell counts < 250 cells/
μl were detected in 10 patients 4 hr after dosing and in
3 patients 24 hr after dose administration. No apparent
safety-related significance was attributed to this transi-
ent reduction in CD4 T cell counts, and prior to the
second dose administration CD4 T cell counts were
above 250 cells/μl in all patients.
Immunogenicity
Anti-therapeutic antibodies were detected post dose in
three MTRX1011A treated patients. The systemic expo-
sure to MTRX1011A in these three patients was similar
to the systemic exposure to MTRX1011A in the other
patients in the respective cohorts, indicating that the
presence of anti-MTRX1011A antibodies did not appear
to impact the systemic exposure to MTRX1011A.
Pharmacokinetics
MTRX1011A exhibited non-linear PK properties in the
dose ranges tested, as was expected for an antibody with
high target mediated clearance (CL). The mean total CL
ranged from 79 to 8.1 ml/kg/day for the 0.3 to 7.0 mg/
kg single dose IV cohorts, respectively, and 6.2 ml/kg/
day for the 5 mg/kg multi-dose IV cohort. Absolute SC
bioavailability was estimated to be approximately 52%.
Modest accumulation was observed upon multiple
weekly dosing at 1.5 to 5 mg/kg SC or IV [14].
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Figure 2 Peripheral blood T cell levels. Blood CD4 T cells in patients after a single dose (A and C) or 8 weekly doses (B and D) of MTRX1011A
in doses ranging from 0.3 to 7.0 mg/kg. Mean CD4 T cells are expressed as cells/μl (A and B) or as % baseline (C and D).
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CD4 expression and occupancy
Immediately following dose administration, the expres-
sion of CD4 on peripheral blood T cells was dose
dependently decreased. Maximum down modulation of
CD4 was approximately 75% and observed in the
cohorts receiving 1, 3.5 and 7 mg/kg MTRX1011A IV in
the SAD phase. As plasma levels of MTRX1011A
decreased over time, CD4 expression levels returned to
pre-dose levels in a dose dependent manner. The
remaining CD4 sites on peripheral blood T cells were
occupied with MTRX1011A in a dose dependent man-
ner. Twenty-four hours after MTRX1011A administra-
tion no available CD4 sites on peripheral blood T cells
were detected in the cohorts receiving 1, 3.5 and 7 mg/
kg MTRX1011A IV, indicating complete CD4 receptor
occupancy. MTRX1011A induced CD4 down-modula-
tion and occupancy in the SC cohorts as well, but not
to the same extent in the high dose IV groups. In con-
trast to prior studies with the depleting anti-CD4 anti-
body cM-T412, in which preferential PD effects were
observed on naïve T cells compared to memory T cells
[22], in our study CD4 receptor down-modulation and
CD4 receptor occupancy in MRX1011A treated groups
was identical between naïve and memory CD4 T cell
subsets. Figure 3 presents the effect on the PD effects of
MTRX1011A on the memory CD4CD45RA- T cell sub-
set. Weekly doses of 1.5 mg/kg MTRX1011A were not
sufficient to maintain CD4 down-modulation and CD4
receptor occupancy during the dosing phase whereas in
both of the 3.5 mg/kg SC and the 5 mg/kg IV weekly
cohorts maximum PD effects of MTRX1011A were
maintained between weekly dose administrations (Figure
3B, D).
Immunophenotyping
To further characterize the effect of MTRX1011A on
the immune system, we performed a phenotypical analy-
sis of peripheral blood lymphocyte subsets. No effects
were observed of MTRX1011A treatment on the num-
ber of memory or naïve T and B cell subsets. Strikingly,
a significant increase in CD69 expression was observed
on both naïve and memory CD4 T cell subsets during
the dosing phase of MTRX1011A (Figure 4B). An addi-
tional activation marker, CD25 was not affected by
MTRX1011A treatment on T cell subsets.
Serum analytes
CD4 is also present in the serum in a soluble form
(sCD4) due to post-translational shedding from the sur-
face of the cell [23]. Upon dose administration
MTRX1011A bound to this soluble form of CD4, and
elevated sCD4-levels were detected in the serum (Figure
4A). It was assumed that all sCD4 measured was in
complex with MTRX1011A because of the molar excess
of MTRX1011A to sCD4. Serum levels of CD4-
MTRX1011A complexes dose-dependently increased in
ascending dose cohorts and were approximately stable
at steady state MTRX1011A exposure. Serum levels of
the inflammatory cytokines GM-CSF, IFNg,I L 1 0 ,
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Figure 3 Peripheral blood CD4 expression and CD4 occupancy. Mean changes in peripheral blood CD4 expression and CD4 occupancy on
memory (CD45RA-) CD4 T cells in patients receiving placebo or MTRX1011A in the single dose (A and C) and multiple dose (B and D) phase of
the study when administered intravenously (IV) or subcutaneously (SC) at doses ranging from 0.3 to 7 mg/kg. A and B, MTRX1011A treatment
induced a dose dependent down modulation of CD4 expression on peripheral blood memory CD4 T cells. C and D, MTRX1011A administration
resulted in a dose dependent occupancy of CD4 sites on peripheral blood memory CD4 T cells.
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Page 7 of 11IL12p70, IL1b,L L 2 ,I L 6 ,I L 8a n dT N F a were not
affected by MTRX1011A dosing, and levels of sCD25
were also not elevated (data not shown).
In summary, these PD biomarker data demonstrate
that MTRX1011A dosing affects peripheral blood T
cells in several ways. CD4 T cells were transiently
reduced, CD4 receptor expression was down-modulated,
sCD4 levels in serum were elevated and elevated CD69
expression was observed on CD4 T cells suggesting low
levels of T cell activation without detection of concomi-
tant cytokine release at the measured time points.
Clinical activity
The effect of MTRX1011A on disease activity was evalu-
ated only in the MD phase. A slightly higher proportion
of patients in the 3.5 mg/kg SC MTRX1011A treated
group achieved an ACR20, ACR50 and ACR70 response
at eight weeks when compared to patients treated with
placebo (Table 3). ACR20, ACR50 and ACR70 response
rates were 33, 25, and 8%, respectively, for the 3.5 mg/
kg MTRX1011A patients compared to 14, 0 and 0%,
respectively, for the placebo treated patients. Patients
receiving this dose demonstrated improvements in the
mean SJC, which were reduced by 12 (60%) at Week 8
compared to baseline, and in mean TJC, which were
reduced by 23 (56%) at Week 8 compared to baseline.
Additionally, MTRX1011A treatment led to some minor
i m p r o v e m e n ti nD A S - C R P ,D A S - E S R ,E S R ,a n dp a i n
intensity; however, these improvements were also
observed in patients treated with placebo and were not
considered clinically significant. Taken together these
assessments of disease activity suggest that treatment
with 3.5 mg/kg MTRX1011A weekly for eight doses
may lead to modest improvement in some markers of
disease activity.
Discussion
In this study, we report the safety, tolerability, pharma-
cokinetics, and pharmacodynamics of MTRX1011A in
patients with RA. MTRX1011A was tolerated up to
doses of 1.5 mg/kg administered weekly SC for eight
doses; however, at doses of 3.5 mg/kg SC weekly and
5.0 mg/kg IV weekly a moderate erythematosus papular
pruritic rash was observed in some patients and consid-
ered dose limiting for this clinical indication. Though
apparent maximum CD4 down-modulation and full
CD4 occupancy were achieved and maintained in the
3.5 mg/kg SC MD cohort, only modest clinical activity
was observed.
Overall, the results from this study are in agreement
with previously reported studies evaluating safety, toler-
ability and efficacy of anti-CD4 treatments. Some evi-
dence of clinical activity hasb e e nd e m o n s t r a t e dw i t h
earlier anti-CD4 antibodies 4162W94, and keliximab,
whereas a randomized Phase I/II study with clenolixi-
mab demonstrated significant improvement in ARC20
responses [15-17]. Despite achieving maximum PD
activity in peripheral blood in the weekly 3.5 mg/kg SC
and 5 mg/kg IV dose groups, the clinical benefit of
MTRX1011A treatment was only modest in the current
-10 0 10 20 30 40
0
100
200
300
Placebo
0.3 mg/kg IV
1 mg/kg IV
1 mg/kg SC
3.5 mg/kg IV
3.5 mg/kg SC
7 mg/kg IV
Day
s
C
D
4
 
(
n
g
/
m
l
)
0 50 100
0
100
200
300
400
500
1.5 mg/kg SC
3.5 mg/kg SC
Placebo
5 mg/kg IV
Day
s
C
D
4
 
 
(
n
g
/
m
l
)
-10 0 10 20 30 40
0
500
1000
1500
Placebo
0.3 mg/kg IV
1 mg/kg IV
1 mg/kg SC
3.5 mg/kg IV
3.5 mg/kg SC
7 mg/kg IV
Day
%
C
D
6
9
 
(
%
 
b
a
s
e
l
i
n
e
)
0 50 100
0
500
1000
1500
1.5 mg/kg SC
3.5 mg/kg SC
Placebo
5 mg/kg IV
Day
%
C
D
6
9
 
(
%
 
b
a
s
e
l
i
n
e
)
AB
CD
Figure 4 Pharmacodynamic effects of MTRX1011A administration in peripheral blood. Serum levels of soluble CD4-MTRX1011A complexes
increased in a dose dependent fashion in the single dose phase (A) and multi-dose phase (B). MTRX1011A administration intravenously (IV) or
subcutaneously (SC) lead to significant increase in CD69 expression on memory CD4 T cells in the single dose phase (C) and multi-dose phase
(D).
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Page 8 of 11Table 3 Clinical activity assessments in the multi dose phase at eight weeks
Placebo MTRX1011A 1.5 mg/kg SC MTRX1011A 3.5 mg/kg SC MTRX1011A 5.0 mg/kg IV
baseline eight weeks baseline eight weeks baseline eight weeks baseline eight weeks
ACR20, % patients 14 8 33 25
ACR50, % patients 0 0 25 0
ACR70, % patients 0 0 8 0
DAS-CRP 5.4 (4.3 to 6.6) 4.4 (3.2 to 5.9) 5.7 (4.1 to 6.7) 5.6 (4.0 to 7.7) 5.9 (3.7 to 6.8) 4.6 (2.6 to 6.8) 6.5 (4.2 to 8.0) 5.5 (3.2 to 6.8)
CRP, mg/dL 1.7 (0.03 to 4.0) 1.1 (0.1 to 3.0) 0.8 (0.02 to 2.3) 1.1 (0.02 to 4.2) 1.1 (0.02 to 7.7) 1.7 (0.1 to 9.8) 2.1 (0.1 to 8.2) 1.1 (0.1 to 3.9)
ESR, mm/hour 47 (15 to 120) 36 (8 to 104) 32 (8 to 60) 30 (6 to 108) 39 (0 to 78) 34 (8 to 58) 61 (26 to 110) 51 (29 to 104)
SJC 7 (0 to 16) 7 (0 to 19) 14 (2 to 30) 18 (2 to 51) 20 (7 to 52) 8 (0 to 36) 26 (3 to 59) 17 (0 to 30)
TJC 36 (10 to 53) 25 (3 to 62) 42 (12 to 65) 37 (4 to 67) 41 (8 to 68) 18 (0 to 66) 48 (22 to 65) 30 (24 to 33)
VAS,
Patient, pain 60 (42 to 77) 39 (19 to 57) 57 (17 to 79) 59 (10 to 89) 62 (18 to 91) 54 (14 to 89) 78 (62 to 90) 47 (20 to 67)
Patient, overall 69 (54 to 94) 43 (18 to 75) 63 (17 to 98) 58 (17 to 88) 70 (40 to 93) 56 (10 to 87) 81 (60 to 100) 52 (25 to 75)
VAS, Physician, global 60 (26 to 78) 44 (25 to 63) 51 (21 to 80) 52 (12 to 88) 66 (35 to 100) 51 (13 to 88) 58 (45 to 76) 52 (33 to 73)
Data are expressed as group mean, with ranges depicted between parentheses. ACR, American College of Rheumatology; CRP, C-reactive protein; DAS, disease activity score; ESR, erythrocyte sedimentation rate; IV,
intravenous; SC, subcutaneous; SJC, swollen joint count; TJC, tender joint count; VAS, visual analog scale.
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1study. Moreover, in three patients in the MD study trea-
ted with MTRX1011A a subjective worsening in disease
activity was reported. Interestingly, in these patients
CD4 down-modulation and occupancy was not main-
tained between dose administrations (data not shown).
It is possible that studies investigating longer treatment
duration could have shown more pronounced clinical
efficacy had these dose levels been well tolerated.
The main objective of this Phase I study was to assess
safety and tolerability, and 1.5 mg/kg SC weekly of
MTRX1011A was established as the maximum tolerated
dose. Given the known relationship between PD activity
and efficacy, CD4 expression and occupancy PD assess-
ments were incorporated to evaluate if MTRX1011A
was able to achieve these predefined PD criteria at safe
and tolerated dose levels. In this small phase I study, we
were able to clearly demonstrate that the maximum tol-
erated dose of 1.5 mg/kg SC weekly was not sufficient
to maintain the required maximum PD between dose
administrations, and therefore, further development of
MTRX0111 for the treatment of patients with RA was
halted.
Incorporating measurements of PD activity in early clin-
ical studies can support decision making and ensure that
only molecules with increased chances of success will pro-
gress to the next stage of development. A thorough under-
standing of the mechanism of action of a therapeutic
based on preclinical studies is critical to start with, and
translating this knowledge to early clinical development
and exploring detailed pharmacological measurements in
human disease will ultimately benefit patients by providing
safe and effective novel therapeutics.
Most previous anti-CD4 therapeutics have been asso-
ciated with increased incidence of rash, and in this
study MTRX1011A also induced a dose-limiting moder-
ate pruritic rash [15,17,20]. The occurrence of rash is
evidently associated with direct targeting of the CD4
molecule, but the mechanism of rash formation is not
understood. The observation that the rash occurred
typically after the third or fourth dose administration
and was not limited to the injection site is indicative
that an immunological response plays a role in its for-
mation. We incorporated extensive pharmacological
measurements to try to elucidate the mechanism by
which MTRX1011A could cause rash in some patients.
The observed increase in CD69 expression on T cells
clearly demonstrates that in vivo MTRX1011A adminis-
tration leads to an immediate and dose dependent early
activation of T cells. In patients experiencing rash, the
mean CD69 expression was slightly higher than that of
other patients; however, given the small number of inci-
dences observed in the study, we were not able to
demonstrate a clear correlation between the extent of
CD69 up-regulation and rash formation. Neither did we
observe a clear correlation between the increased sCD4
levels following MTRX1011A administration and rash
formation. Additional potential correlations between
cases of rash and baseline CD4 counts, anti-
MTRX1011A antibodies, serum cytokine levels did not
identify a causal relationship (data not shown). The
biopsy result of pallisaded neutrophilic and granuloma-
tous dermatitis (PNGD) in one patient represents an
interesting finding that has been described as a rare
entity with an unknown etiology associated with (1)
multiple disorders–mostly RA as well as other connec-
tive tissue disorders, (2) exposure to medications, and
(3) myeloproliferative disorder [24-27]. Deposition of
immune complexes in dermal tissues and the presence
of IgM and C3 in dermal vessels and at the dermal-epi-
dermal junction in PNGD patients have been reported
[26,27].
Conclusions
This study demonstrated that MTRX1011A was tolerated
at weekly SC doses up to 1.5 mg/kg for eight doses. How-
ever, at this dose, MTRX1011A did not maintain maxi-
mum PD responses between weekly administrations, and
higher dose levels that maintained maximum PD
response were associated with dose-limiting rash. The
cause of the pruritic rash remains elusive but is clearly
associated with targeting CD4. Furthermore, only modest
reduction in disease activity was observed even at doses
above the maximum tolerated dose when maximum PD
was maintained. Although CD4 T cells are certainly
involved in the pathogenesis of RA, data from this study
and those published by others have shown that targeting
CD4 T cells with an anti-CD4 antibody is associated with
at best a modest improvement in clinical parameters.
Furthermore, this study also provides a model for the use
of pharmacodynamic biomarkers in early decision mak-
ing in clinical development.
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